-
Mashup Score: 34Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation - 14 day(s) ago
Classically, the optimal donors for patients requiring hematopoietic stem cell transplantation (HSCT) have been HLA-matched relatives or unrelated donors in the National Marrow Donor Program registry. For many patients, such as those of an ethnic minority, an HLA-matched donor might not be available [1]. Haploidentical HSCT (haplo-HSCT) has provided additional donor options for most patients who lack an HLA-matched donor. Potential donors for haplo-HSCT include parents, siblings, and children.
Source: www.astctjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic challenge. There is substantial variability across transplantation and cellular therapy programs in assessing and managing post CAR-T failures in RRMM. The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines conducted an online cross-sectional survey between September 2023 and December 2023 to determine the myeloma, transplantation and cellular therapy physicians’ practice patterns for surveillance, diagnosis, and management of CAR-T failure.
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary - 26 day(s) ago
Chimeric antigen receptor-modified T cell (CAR-T) therapy has become a critical part of the armamentarium for the treatment of relapsed/refractory hematologic malignancies. As our experience with CAR-T therapy grows and new data emerge, the identification of suitable patients has become more complex. The Community Oncologist Patient ID Roundtable, held on May 16, 2023, brought together 3 professional societies— (American Society for Transplantation and Cellular Therapy [ASTCT], Association of Community Cancer Centers [ACCC], and Association of American Cancer Institutes [AACI])—with the aim of developing a standardized framework to enable community oncology care teams to assess patients more easily for CAR T consultation, with a focus on large B cell lymphoma (LBCL).
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 13Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production - 1 month(s) ago
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies that lead to immune complex-induced inflammation in an array of different organs including the kidneys, heart, lungs and skin. The pathogenesis of SLE is complex and relies on genetic, endogenous, environmental and immunoregulatory factors1. The central role of B cells in SLE is supported by the presence of B cells in diseased tissues, clonal expansion and plasmablast generation. Monoclonal antibodies that disrupt B cell activation or deplete B cells have been used to treat autoimmune diseases like SLE.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies—idecabtagene vicleucel (ide-cel; Bristol Myers Squibb), and ciltacabtagene autoleucel (cilta-cel; Janssen Biotech)—have been approved by the US Food and Drug Administration (FDA) for relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody [1–3]. The 2 products have shown unprecedented activity in RRMM, but relapse remains common in the late-line setting, where many patients have bulky, rapidly growing high-risk disease that may decrease both efficacy and safety.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 18
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure for a variety of hematologic malignancies [1]. Historically, the availability of an HLA-matched donor was required for successful outcomes of HCT, to minimize the risk of graft rejection, graft-versus-host disease (GVHD), and nonrelapse mortality (NRM). An HLA-matched sibling donor (MSD) is the preferred donor, but this donor option is available in only 30% of patients [2]. In the absence of an MSD, an HLA-matched unrelated donor (MUD) may be identified through volunteer donor databases.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure for a variety of hematologic malignancies [1]. Historically, the availability of an HLA-matched donor was required for successful outcomes of HCT, to minimize the risk of graft rejection, graft-versus-host disease (GVHD), and nonrelapse mortality (NRM). An HLA-matched sibling donor (MSD) is the preferred donor, but this donor option is available in only 30% of patients [2]. In the absence of an MSD, an HLA-matched unrelated donor (MUD) may be identified through volunteer donor databases.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy - 2 month(s) ago
Chimeric antigen receptor T cells (CAR-T) targeting the B-cell maturation antigen (BCMA) have transformed the care of patients with relapsed/refractory (R/R) multiple myeloma (MM). Outcomes reported in pivotal studies have led to the approval of 2 anti-BCMA CAR-T therapy products, idecabtagene vicluecel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which have demonstrated significant improvements over prior standard of care in patients with triple-class exposed (TCE) RRMM [1–4]. The response rates to these therapies range between 73% and 98% [1,2,5].
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy - 2 month(s) ago
CD19-targeted chimeric antigen receptor T cell therapy (CAR-T) is a novel treatment for patients with relapsed/refractory (R/R) B cell malignancies, including non-Hodgkin lymphoma (NHL) [1,2]. CD19 is essential for key B cell differentiation events and declines as B cells terminally differentiate into plasma cells [3,4]. This suggests that some memory antibody responses may persist even if all CD19+ cells are eradicated [5]. Ongoing CAR-T activities may result in persistent CD19+ B cell aplasia and hypogammaglobulinemia, with a consequent risk of infection [6] (Figure 1A).
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both clinical trials and the real-world setting, but at the cost of prolonged patient hospitalization. As the toxicity management protocols were refined, the concept of cellular therapy administered in the outpatient setting gained steam, and single institutions began to perform certain aspects of CAR-T monitoring in the outpatient setting for select patients.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical- Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy https://t.co/L5hlo9a9Ze